Form 4: Column Group II, LP Exchanges RAPT Therapeutics Shares for Pre-Funded Warrants

Column Group II, LP and Ponoi Capital, LP exchanged RAPT Therapeutics shares for pre-funded warrants on December 23, 2024.

Summary

• On December 23, 2024, The Column Group II, LP (TCG II LP) and Ponoi Capital, LP (Ponoi LP) entered into an exchange agreement with RAPT Therapeutics, Inc.
• TCG II LP and Ponoi LP exchanged 1,352,008 and 1,599,417 shares of RAPT Therapeutics Common Stock, respectively, for pre-funded warrants.
• The pre-funded warrants allow the purchase of 1,352,008 and 1,599,417 shares of Common Stock, respectively.
• The exercise price for the pre-funded warrants is $0.0001 per share.
• The pre-funded warrants were issued on December 23, 2024.
• Various entities and individuals associated with The Column Group and Ponoi Capital may be deemed to have beneficial ownership of the securities, but disclaim beneficial ownership except to the extent of their pecuniary interest.
• The pre-funded warrants have no expiration date and are exercisable at any time after issuance, subject to a 4.99% ownership limitation.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The exchange of shares for pre-funded warrants indicates continued investor confidence, but the complex ownership structure and disclaimers warrant careful consideration.

Positives

• The exchange provides RAPT Therapeutics with immediate capital while allowing the investors to maintain their potential ownership stake.
• The pre-funded warrants have a very low exercise price, indicating a strong commitment from the investors.

Risks

• The 4.99% ownership limitation on the pre-funded warrants could restrict the investors' ability to fully exercise their warrants if it would result in exceeding that threshold.
• The disclaimer of beneficial ownership by various entities and individuals could indicate a complex ownership structure that warrants further investigation.

Future Outlook

The document does not contain explicit forward-looking statements from the company, but the issuance of pre-funded warrants suggests continued financial backing from key investors.

Industry Context

This type of transaction, where shares are exchanged for pre-funded warrants, is often used by biotech companies to raise capital while providing investors with the potential for future equity ownership. It's a common financing strategy in the biotech industry.

Comparison to Industry Standards

• Similar transactions can be seen with other biotech companies such as [hypothetical company A] and [hypothetical company B], where pre-funded warrants were used to secure funding for clinical trials.
• The exercise price of $0.0001 is very low, which is not uncommon for pre-funded warrants as the investors have already provided the capital.
• The 4.99% ownership limitation is a standard clause to avoid triggering certain regulatory requirements.

Stakeholder Impact

• Shareholders may see this as a positive sign of continued investor support.
• The transaction provides the company with additional financial flexibility.

Key Dates